NKGN

7.02% -0.010

Handel nachbörslich: .13 -0.0025 -1.89%

Nkgen Biotech Inc (NKGN)

Überblick Nachrichten Preisverlauf Warum fällt NKGN? Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Nkgen Biotech Inc Stock (NKGN) Company Profile

Nkgen Biotech Inc

Healthcare (1152)

Biotechnology (648)

Nächster Verdiensttermin

Neueste SEC-Einreichungen

NKGN's Discussions on Twitter

Vergleichen Sie NKGN mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
NKGN Nkgen Biotech Inc	0.1325	0	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	394.53	99.62B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	465.89	61.52B	2.46B	-319.09M	-52.09M	-2.47
REGN Regeneron Pharmaceuticals Inc	560.00	58.91B	14.21B	4.46B	3.56B	39.68
ARGX Argen X Se Adr	756.38	46.69B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	324.34	34.54B	3.81B	-644.79M	-669.77M	-6.24

Nkgen Biotech Inc Aktie (NKGN) Neueste Nachrichten

Finanzdaten der Nkgen Biotech Inc-Aktie (NKGN)

Es liegen keine Finanzdaten für Nkgen Biotech Inc (NKGN) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Nkgen Biotech Inc (NKGN)

Nkgen Biotech Inc Stock (NKGN) Company Profile

Vergleichen Sie NKGN mit anderen Aktien

Nkgen Biotech Inc Aktie (NKGN) Neueste Nachrichten

NKGen Biotech announces completion of NKMax acquisition - MSN

NKGen Biotech Acquires Majority Stake in NKMax - TipRanks

NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. Acquisition; Gains Full Control of Global Manufacturing and Intellectual Property Assets - The Manila Times

NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. - GlobeNewswire

$16.9M Strategic Acquisition: NKGen Biotech Gains Full Control of NK Cell Therapy Manufacturing & IP Portfolio - Stock Titan

Cell Dissociation Market Size Projected to Attain USD 1,451.89 Million by 2034 - GlobeNewswire

Alzheimer's Disease Pipeline 2025: Detailed Clinical Trials And FDA-Approved Therapies Review By Delveinsight Neurodon, Sangamo Therapeutics, Nkgen Biotech, Asceneuron, Truebinding, Alector - MenaFN

NKGen Biotech, Inc. (NYSE:NKGN) Short Interest Update - Defense World

NKGen Biotech To Present on Allogeneic Enhanced NK Cells - GlobeNewswire

Breakthrough: NKGen's NK Cell Cancer Therapy Eliminates Need for Harsh Pre-Treatment in Solid Tumors - Stock Titan

NKGen Biotech To Present on Allogeneic Enhanced NK Cells without Lymphodepletion in Solid Tumors at the 13th Annual Immuno-Oncology Summit - The Manila Times

Critical Contrast: NKGen Biotech (NYSE:NKGN) & Cortexyme (NASDAQ:CRTX) - Defense World

NKGen Biotech Presents Troculeucel Mechanism of Action with - GlobeNewswire

Revolutionary NK Cell Therapy Transforms Moderate Alzheimer's to Mild Stage in Clinical Trial - Stock Titan

NKGen Biotech to Present at the Alzheimer’s Association International Conference 2025 - GlobeNewswire

Revolutionary NK Cell Therapy Shows Promise in Alzheimer's Disease: Phase 1 Data Reveal Key Insights - Stock Titan

NKGen Biotech Gets FDA Expanded Access - Orange County Business Journal

NKGen Secures FDA Expanded Access For NK Cell Therapy In Neurodegenerative Diseases, Stock Down - Nasdaq

FDA grants expanded access for NKGen’s cell therapy in neurodegenerative diseases By Investing.com - Investing.com South Africa

FDA grants expanded access for NKGen’s cell therapy in neurodegenerative diseases - Investing.com Nigeria

NKGen Receives FDA Expanded Access Protocol Authorization for Landmark Treatment of Several Neurodegenerative Diseases - The Manila Times

NKGen Receives FDA Expanded Access Protocol Authorization - GlobeNewswire

FDA Grants Breakthrough Access: NKGen's NK Cell Therapy Now Available for Multiple Untreatable Brain Diseases - Stock Titan

NKGen Biotech and HekaBio enter strategic partnership to bring novel NK cell therapy to Japan - BioSpectrum Asia

NKGen and HekaBio partner to advance NK cell therapy in Japan - Investing.com India

NKGen Biotech Partners with HekaBio for SNK01 in Japan - TipRanks

NKGen and HekaBio partner to advance NK cell therapy in Japan By Investing.com - Investing.com South Africa

NKGen Biotech and HekaBio Enter Strategic Partnership to Bring Novel NK Cell Therapy to Japan - GlobeNewswire

Vivos Therapeutics shares rise 1.81% premarket after NKGen Biotech's new funding announcement. - AInvest

NKGen Biotech announces new funding to regain compliance with reporting obligations and listing standards - MSN

NKGen Biotech Announces New Funding to Regain Compliance with Reporting Obligations and Listing Standards - GlobeNewswire

NKGen Biotech Secures Funding Amid Compliance Challenges - TipRanks

NKGen Biotech (NYSE:NKGN) versus CEL-SCI (NYSE:CVM) Head-To-Head Comparison - Defense World

Nasdaq Announces Delisting of Multiple Companies Including NKGen Biotech, Aquaron Acquisition Corp, and Others - Quiver Quantitative

Delisting of Securities from The Nasdaq Stock Market - Yahoo Finance

NKGen Biotech (NYSE:NKGN) Stock Price Down 0.2% – What’s Next? - Defense World

NKGen administers first dose of NK cell therapy to Alzheimer’s patient - Investing.com Australia

NKGen administers first dose of NK cell therapy to Alzheimer’s patient By Investing.com - Investing.com South Africa

NKGen Biotech Administers First Dose of Troculeucel to - GlobeNewswire

Breakthrough: New NK Cell Treatment Offers Hope for Alzheimer's Patients Who Failed Standard Therapy - Stock Titan

NKGen activates new sites for Phase I/IIa study of Alzheimer’s cell therapy - Clinical Trials Arena

NKGen Biotech Announces International and U.S. Expansion of - GlobeNewswire

NKGen Biotech Approved as Preferred Bidder for NKMAX - TipRanks

A waste business buy, slashing salaries for all staff: 4 strange strategies biotechs are using to stay alive - Fierce Biotech

NKMAX completes sale to NKGen, eyes delisting prevention and future recoveryCHOSUNBIZ - Chosun Biz

Nkgen biotech sees $2.5 million stock purchase by major shareholder - Investing.com Canada

NKGen Biotech Enters Stock Purchase Agreement - TipRanks

NKGen Biotech Delays Quarterly Report Filing - TipRanks

NKGen Biotech Chairman & CEO Paul Y. Song, M.D., Personally - GlobeNewswire

NKGen Biotech’s Strategic Stock Purchase Agreement - TipRanks

NKGen Biotech Chairman & CEO Paul Y. Song, M.D., Personally Invests $2.65 Million Cash to Accelerate Phase 2 Clinical Trial and Fulfill Financial Reporting Obligations - Stock Titan

Finanzdaten der Nkgen Biotech Inc-Aktie (NKGN)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie NKGN